Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

Journal of the American College of Surgeons

Volumn 187, Issue 1, 1998, Pages 69-79

  Wallack, Marc K ^a   Sivanandham, Muthukumaran ^a   Balch, Charles M ^b   Urist, Marshall M ^c   Bland, Kirby I ^d   Murray, Douglas ^e   Robinson, William A ^f   Flaherty, Lawrence ^g   Richards, Jon M ^h   Bartolucci, Alfred A ^c   Rosen, Les ⁱ  

^a ST VINCENT S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CHICAGO   (United States)

ⁱ Miami Heart Inst   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINIA ONCOLYSATE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; FEVER; HEADACHE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MELANOMA; METHODOLOGY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTIGENS, NEOPLASM; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; SKIN NEOPLASMS; SMALLPOX VACCINE; VACCINIA VIRUS; VIRAL VACCINES;

EID: 13144275236     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1072-7515(98)00097-0     Document Type: Article

References (9)

1. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage II melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-1044.
2. Livingston PO, Sznol M. Vaccine therapy In: Balch CM, Houghton AN, Sober AJ, Soong S-j, eds. Cutaneous Melanoma 1998: 438-450.
3. Berd D, Murphy G, Maguire HC Jr, et al. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858.
4. Morton DL, Foshag IJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann Surg 217:3091, 1993]. Ann Surg 1992;216:463-482.
5. Mitchell MS, Kan-Mitchell J, Kempf RA, et al. Active-specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988;48:5883-5889.
6. Mitchell MS, Harel W, Kan-Mitchell J, et al. Active-specific immunotherapy for melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action. Ann NY Acad Sci 1993; 690:153.
7. Bystryn JC. Clinical activity of a polyvalent antigen vaccine. Cancer Res 1995;139:337-348.
8. Kirkwood JM, Stawderman MH, Ernstoff MS, et al. Interferon Alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
9. Roenigk HH Jr, Deodhar S, Jasques RS, et al. Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 1974; 109:668-673.